Artivion’s (AORT) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Artivion (NYSE:AORT) in a report released on Monday,Benzinga reports. The firm currently has a $34.00 price target on the stock.

AORT has been the topic of several other reports. JMP Securities started coverage on shares of Artivion in a research report on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 price target on the stock. Stifel Nicolaus increased their price target on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, September 13th. Finally, Oppenheimer increased their price target on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $31.80.

Artivion Trading Down 2.2 %

NYSE AORT opened at $29.00 on Monday. The stock has a market capitalization of $1.22 billion, a P/E ratio of -1,450.00 and a beta of 1.75. Artivion has a 52-week low of $16.48 and a 52-week high of $30.10. The firm has a 50-day moving average price of $27.43 and a 200 day moving average price of $26.07. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Insiders Place Their Bets

In other news, VP Andrew M. Green sold 7,618 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the transaction, the vice president now owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. This trade represents a 18.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Amy Horton sold 4,329 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the transaction, the chief accounting officer now directly owns 135,660 shares in the company, valued at approximately $4,023,675.60. This represents a 3.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,377 shares of company stock valued at $682,356 over the last quarter. Company insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Artivion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in Artivion during the 2nd quarter worth $28,000. Quarry LP grew its holdings in Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after acquiring an additional 820 shares in the last quarter. RiverPark Advisors LLC acquired a new position in Artivion during the 2nd quarter worth $55,000. RW Investment Management LLC acquired a new position in Artivion during the 2nd quarter worth $219,000. Finally, Intech Investment Management LLC acquired a new position in Artivion during the 2nd quarter worth $253,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.